Vaccines (Jul 2024)

Immunogenicity, Safety and Efficacy of the Dengue Vaccine TAK-003: A Meta-Analysis

  • Maria Elena Flacco,
  • Alessandro Bianconi,
  • Giovanni Cioni,
  • Matteo Fiore,
  • Giovanna Letizia Calò,
  • Gianmarco Imperiali,
  • Vittorio Orazi,
  • Marco Tiseo,
  • Anastasia Troia,
  • Annalisa Rosso,
  • Lamberto Manzoli

DOI
https://doi.org/10.3390/vaccines12070770
Journal volume & issue
Vol. 12, no. 7
p. 770

Abstract

Read online

The TAK-003 dengue vaccine was licensed in Europe in December 2022, and the official recommendations from most EU countries are still under formulation. To support policymakers, we performed a meta-analysis to quantify TAK-003’s immunogenicity, efficacy and safety among seronegative and seropositive populations after the administration of one or two vaccine doses. We included trials retrieved from MEDLINE, Scopus and ClinicalTrials.gov. The outcomes were the rates of seroconversion, virologically confirmed dengue fever and serious adverse events after each vaccine dose. Data were combined using random-effect proportion or head-to-head meta-analyses. We retrieved a total of 19 datasets, including >20,000 participants. TAK-003 showed an excellent safety profile, and the immunogenicity after two doses against the four DENV serotypes was ≥90% among both adults and children/adolescents who were either seronegative or seropositive at baseline. A single dose was able to elicit a high immunogenic response among adults (≥70%) and children/adolescents (≥90%). The primary two-dose immunization course halved the risk of all types of virologically confirmed dengue fever among seropositive children/adolescents, but seronegative minors were only protected against the diseases caused by DENV-1 and DENV-2. Overall, the results support the use of TAK-003 for the prevention of dengue fever in the pediatric population of endemic countries. Uncertainties remain on the use of a single vaccine dose in non-endemic countries.

Keywords